ArticleScientific reports2022
The relationship between systemic immune inflammation index and survival in patients with metastatic renal cell carcinomatreated withtyrosine kinase inhibitors.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The prognostic impact of systemic inflammation and nutritional indicators on targeted therapy for renal cell carcinoma: a systematic review and meta-analysis.Frontiers in nutrition · 2026Pooled it
- Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis.Frontiers in oncology · 2024Pooled it
- The impact of bariatric surgery and exercise on systemic immune inflammation index in patients with sarcopenia obesity.Scientific reports · 2025Trial
- Prognostic value of systemic immune-inflammation index in patients with localized and advanced renal cell carcinoma: a systematic review and meta-analysis.Translational andrology and urology · 2026Article
- Prognostic Impact of Metastatic Pattern in Renal Cell Carcinoma: IMDC, IMDC-7, and Meet-URO Scores.Journal of kidney cancer and VHL · 2026Article
- Integrative bioinformatics analysis for identifying the mitochondrial-related gene associated with immune infiltration in sarcopenia.Medicine · 2025Article
- Uric acid level in metastatic renal cell carcinoma treated with nivolumab: a Turkish Oncology Group Kidney Cancer Consortium (TKCC) study.Immunotherapy · 2025Article
- Relationship between uric acid to high-density lipoprotein cholesterol ratio and sarcopenia in NHANES: exploring the mediating role of bilirubin and association with all-cause mortality.Frontiers in nutrition · 2025Article
- Navigating second-line therapy in metastatic renal cell carcinoma: a comparative analysis of immune checkpoint inhibitors and tyrosine kinase inhibitors: a study of Turkish Oncology Group Kidney Cancer Consortium.Therapeutic advances in medical oncology · 2025Article
- Association between systemic immune-inflammation index and chronic kidney disease: A population-based study.PloS one · 2024Article
- Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18-59 years: a population-based study.Scientific reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kinase inhibitors (TKIs)between January 2007 and June 2020 (i.e., sunitinib, pazopanib) were included in this study. SII was calculated in 621 patients with the following formula:[neutrophil (cellsx10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.